{"success":true,"data":{"pressRelease":{"id":"129757","rtpr_id":"nBw6nB8nba","ticker":"PHG","exchange":"NYSE","all_tickers":["PHG","IMR"],"title":"Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration","author":"Business Wire","published_at":"2026-08-27T19:27:00.072Z","article_body":"Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding\nLongstanding Collaboration\n\nRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology,\nand Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer\nof MR-compatible products for interventional MR procedures, today announced a\nnew Interventional MR (iMR) lab solution for Philips 1.5T MR. The first\ncommercially available configuration* combines Philips’ 1.5T MRI platform\nand Imricor's portfolio of iMR systems and consumables, enabling an MR-guided\nworkflow for cardiac intervention, without compromising on MR field strength.\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20260827693715/en/\n(https://www.businesswire.com/news/home/20260827693715/en/)\n\nMeeting the need for greater tissue insight during cardiac intervention\n\nCardiac arrhythmias affect millions of people worldwide, and catheter ablation\nis an established and increasingly utilized treatment for many complex cardiac\narrhythmias. Yet today, these procedures continue to rely primarily on X-ray\nfluoroscopy, which provides only indirect visualization of soft tissue while\nexposing patients and clinical teams to ionizing radiation.\n\nMRI has already transformed cardiac diagnosis by enabling clinicians to\nvisualize cardiac anatomy and tissue in exceptional detail. Bringing that same\nlevel of tissue insight into intervention has the potential to help physicians\nguide therapy more precisely, assess treatment response during procedures and\nidentify potential therapy gaps before a patient leaves the procedure room –\nall within a radiation-free work environment of an iMR.\n\n\"Our ambition is not only to advance what clinicians can see with MRI, but\nalso what they can do with it,\" said Ioannis Panagiotelis, PhD, Business\nLeader, Magnetic Resonance at Philips. \"Philips has a long history of helping\nclinicians perform image-guided procedures with confidence, and we believe MRI\ncan play an even greater role in providing care. With this new iMR lab\nsolution, enabled through our collaboration with Imricor, we're expanding the\nrole of cardiac MRI from diagnosis into the treatment environment.\"\n\nPanagiotelis added, \"Cardiac electrophysiology is just the beginning. This iMR\nlab solution represents an important step in Philips' strategy to advance MRI\nacross the care continuum, creating a platform that can expand into additional\nclinical areas while helping clinicians deliver the best possible care for\ntheir patients.\"\n\niMR built on Philips’ leading cardiac 1.5T MRI platform\n\nThe iMR lab solution combines Philips' high-performance 1.5T MRI platform with\nImricor's portfolio of MR-compatible systems and consumables to create a\ncomplete, connected environment for MR-guided cardiac intervention – marking\nthe next milestone in the companies' long-standing collaboration to bring\nMR-guided cardiac intervention into routine clinical practice.\n\nThe first commercially available configuration includes Philips' Cardiac MR\nSuite, featuring SmartHeart AI-powered cardiac planning and advanced cardiac\nimaging applications alongside Imricor's NorthStar® iMR mapping and guidance\nsystem, Advantage-MR® EP Recorder/Stimulator and Vision-MR® family of\nelectrophysiology catheters**. Together, these technologies enable physicians\nto visualize cardiac anatomy and arrhythmia substrate, actively track\ncatheters, perform electroanatomical mapping, assess lesion formation and\nevaluate treatment response throughout procedures within Philips' 1.5T MR\nenvironment.\n\nFor hospitals, the iMR lab solution provides a turnkey platform for MR-guided\ncardiac intervention, bringing together advanced imaging, intelligent\nworkflows and MR-compatible interventional technologies. The solution is built\non Philips' BlueSeal helium-free MRI technology***, reducing siting complexity\nand enabling installation closer to cardiology departments, helping support\nadoption today while establishing a scalable foundation for future iMR-guided\nprocedures.\n\n“With interventional MR, the idea is not to move procedures into diagnostic\nMRI suites, but rather to bring MR imaging into the procedure room, a room we\ncall an iMR lab,\" said Steve Wedan, Founder and CEO of Imricor. “Our\ncollaboration with Philips has always been driven by this shared vision, and\nwith our combined iMR lab solution, that vision becomes a reality today.\nPairing Philips' world-class 1.5T MR platform with Imricor's exclusive\nportfolio of advanced iMR systems and interventional tools creates the\nworld’s first state-of-the-art high-performance iMR lab solution. We believe\nthe future is about advanced image guidance for therapies and interventions,\nand the future is here now.\"\n\nThe iMR lab solution will be showcased in Munich at ESC Congress 2026 and is\ncommercially available immediately in CE-marked markets and, in some\nconfigurations, the U.S. Further Imricor configurations are expected to become\navailable in the U.S. and additional markets, subject to regulatory\nclearances.\n\n*Philips issued a Third-Party Product Compatibility Declaration for Imricor's\ninterventional MRI (iMR) equipment and consumables.\n\n**NorthStar and the Vision-MR Diagnostic Catheter are commercially available\nin the U.S. Other Imricor products are not yet cleared/approved for sale in\nthe U.S.\n\n***Helium-free operations. 7 liters of helium is permanently enclosed in the\ncryogenic circuit.\n\nAbout Royal Philips\n\nRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company\nfocused on improving people’s health and well-being through meaningful\ninnovation. Philips’ patient- and people-centric innovation leverages\nadvanced technology and deep clinical and consumer insights to deliver\npersonal health solutions for consumers and professional health solutions for\nhealthcare providers and their patients in the hospital and the home.\n\nHeadquartered in the Netherlands, the company is a leader in image-guided\ntherapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics\nand personal health. Philips generated 2025 sales of approximately EUR 18\nbillion and employs approximately 63,700 employees with sales and services in\nmore than 100 countries. News about Philips can be found at\nwww.philips.com/newscenter\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.philips.com%2Fnewscenter&esheet=54595789&newsitemid=20260827693715&lan=en-US&anchor=www.philips.com%2Fnewscenter&index=1&md5=71cb64af9e1964d2f6e272fb01bfe5b5)\n.\n\nAbout Imricor\n\nImricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional\nmedical procedures better, safer, and more cost effective by making it\npossible for these procedures to be performed under real-time magnetic\nresonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus\ntaking advantage of MR’s superior imaging capabilities.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260827693715/en/\n(https://www.businesswire.com/news/home/20260827693715/en/)\n\nPhilips Media Contact: \n\nName: Jayme Maniatis\n\nPhilips Global External Relations\n\nTel.: +16178948368\n\nE-mail: jayme.maniatis@philips.com (mailto:jayme.maniatis@philips.com)\n\nImricor Media Contacts: \n\nSimon Hinsley\n\nExecutive Director, NWR\n\nsimon@nwrcommunications.com.au \n(mailto:simon@nwrcommunications.com.au) \n+61 401 909 653\n\nNick Corkill\n\nVP Corporate Strategy, Imricor\n\nnick.corkill@imricor.com \n(mailto:nick.corkill@imricor.com) \n+61 450 475 633\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6nB8nba","title":"Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration","author":"Business Wire","ticker":"PHG","created":"2026-08-27T19:27:00.072Z","tickers":["PHG","IMR"],"exchange":"NYSE","article_body":"Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding\nLongstanding Collaboration\n\nRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology,\nand Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer\nof MR-compatible products for interventional MR procedures, today announced a\nnew Interventional MR (iMR) lab solution for Philips 1.5T MR. The first\ncommercially available configuration* combines Philips’ 1.5T MRI platform\nand Imricor's portfolio of iMR systems and consumables, enabling an MR-guided\nworkflow for cardiac intervention, without compromising on MR field strength.\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20260827693715/en/\n(https://www.businesswire.com/news/home/20260827693715/en/)\n\nMeeting the need for greater tissue insight during cardiac intervention\n\nCardiac arrhythmias affect millions of people worldwide, and catheter ablation\nis an established and increasingly utilized treatment for many complex cardiac\narrhythmias. Yet today, these procedures continue to rely primarily on X-ray\nfluoroscopy, which provides only indirect visualization of soft tissue while\nexposing patients and clinical teams to ionizing radiation.\n\nMRI has already transformed cardiac diagnosis by enabling clinicians to\nvisualize cardiac anatomy and tissue in exceptional detail. Bringing that same\nlevel of tissue insight into intervention has the potential to help physicians\nguide therapy more precisely, assess treatment response during procedures and\nidentify potential therapy gaps before a patient leaves the procedure room –\nall within a radiation-free work environment of an iMR.\n\n\"Our ambition is not only to advance what clinicians can see with MRI, but\nalso what they can do with it,\" said Ioannis Panagiotelis, PhD, Business\nLeader, Magnetic Resonance at Philips. \"Philips has a long history of helping\nclinicians perform image-guided procedures with confidence, and we believe MRI\ncan play an even greater role in providing care. With this new iMR lab\nsolution, enabled through our collaboration with Imricor, we're expanding the\nrole of cardiac MRI from diagnosis into the treatment environment.\"\n\nPanagiotelis added, \"Cardiac electrophysiology is just the beginning. This iMR\nlab solution represents an important step in Philips' strategy to advance MRI\nacross the care continuum, creating a platform that can expand into additional\nclinical areas while helping clinicians deliver the best possible care for\ntheir patients.\"\n\niMR built on Philips’ leading cardiac 1.5T MRI platform\n\nThe iMR lab solution combines Philips' high-performance 1.5T MRI platform with\nImricor's portfolio of MR-compatible systems and consumables to create a\ncomplete, connected environment for MR-guided cardiac intervention – marking\nthe next milestone in the companies' long-standing collaboration to bring\nMR-guided cardiac intervention into routine clinical practice.\n\nThe first commercially available configuration includes Philips' Cardiac MR\nSuite, featuring SmartHeart AI-powered cardiac planning and advanced cardiac\nimaging applications alongside Imricor's NorthStar® iMR mapping and guidance\nsystem, Advantage-MR® EP Recorder/Stimulator and Vision-MR® family of\nelectrophysiology catheters**. Together, these technologies enable physicians\nto visualize cardiac anatomy and arrhythmia substrate, actively track\ncatheters, perform electroanatomical mapping, assess lesion formation and\nevaluate treatment response throughout procedures within Philips' 1.5T MR\nenvironment.\n\nFor hospitals, the iMR lab solution provides a turnkey platform for MR-guided\ncardiac intervention, bringing together advanced imaging, intelligent\nworkflows and MR-compatible interventional technologies. The solution is built\non Philips' BlueSeal helium-free MRI technology***, reducing siting complexity\nand enabling installation closer to cardiology departments, helping support\nadoption today while establishing a scalable foundation for future iMR-guided\nprocedures.\n\n“With interventional MR, the idea is not to move procedures into diagnostic\nMRI suites, but rather to bring MR imaging into the procedure room, a room we\ncall an iMR lab,\" said Steve Wedan, Founder and CEO of Imricor. “Our\ncollaboration with Philips has always been driven by this shared vision, and\nwith our combined iMR lab solution, that vision becomes a reality today.\nPairing Philips' world-class 1.5T MR platform with Imricor's exclusive\nportfolio of advanced iMR systems and interventional tools creates the\nworld’s first state-of-the-art high-performance iMR lab solution. We believe\nthe future is about advanced image guidance for therapies and interventions,\nand the future is here now.\"\n\nThe iMR lab solution will be showcased in Munich at ESC Congress 2026 and is\ncommercially available immediately in CE-marked markets and, in some\nconfigurations, the U.S. Further Imricor configurations are expected to become\navailable in the U.S. and additional markets, subject to regulatory\nclearances.\n\n*Philips issued a Third-Party Product Compatibility Declaration for Imricor's\ninterventional MRI (iMR) equipment and consumables.\n\n**NorthStar and the Vision-MR Diagnostic Catheter are commercially available\nin the U.S. Other Imricor products are not yet cleared/approved for sale in\nthe U.S.\n\n***Helium-free operations. 7 liters of helium is permanently enclosed in the\ncryogenic circuit.\n\nAbout Royal Philips\n\nRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company\nfocused on improving people’s health and well-being through meaningful\ninnovation. Philips’ patient- and people-centric innovation leverages\nadvanced technology and deep clinical and consumer insights to deliver\npersonal health solutions for consumers and professional health solutions for\nhealthcare providers and their patients in the hospital and the home.\n\nHeadquartered in the Netherlands, the company is a leader in image-guided\ntherapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics\nand personal health. Philips generated 2025 sales of approximately EUR 18\nbillion and employs approximately 63,700 employees with sales and services in\nmore than 100 countries. News about Philips can be found at\nwww.philips.com/newscenter\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.philips.com%2Fnewscenter&esheet=54595789&newsitemid=20260827693715&lan=en-US&anchor=www.philips.com%2Fnewscenter&index=1&md5=71cb64af9e1964d2f6e272fb01bfe5b5)\n.\n\nAbout Imricor\n\nImricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional\nmedical procedures better, safer, and more cost effective by making it\npossible for these procedures to be performed under real-time magnetic\nresonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus\ntaking advantage of MR’s superior imaging capabilities.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260827693715/en/\n(https://www.businesswire.com/news/home/20260827693715/en/)\n\nPhilips Media Contact: \n\nName: Jayme Maniatis\n\nPhilips Global External Relations\n\nTel.: +16178948368\n\nE-mail: jayme.maniatis@philips.com (mailto:jayme.maniatis@philips.com)\n\nImricor Media Contacts: \n\nSimon Hinsley\n\nExecutive Director, NWR\n\nsimon@nwrcommunications.com.au \n(mailto:simon@nwrcommunications.com.au) \n+61 401 909 653\n\nNick Corkill\n\nVP Corporate Strategy, Imricor\n\nnick.corkill@imricor.com \n(mailto:nick.corkill@imricor.com) \n+61 450 475 633\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-27T19:27:00.13248433Z","server_sent_at_ms":1787858820132},"received_at":"2026-08-27T19:27:00.197Z","source_url":"https://www.businesswire.com/news/home/20260827693715/en/"},"analysis":{"id":"118671","press_release_id":"129757","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Philips and Imricor launched the first commercially available Interventional MR lab solution, combining Philips' 1.5T MRI platform with Imricor's MR-compatible systems and consumables.\n\nThe solution enables MR-guided workflows for cardiac interventions like catheter ablation, offering radiation-free procedures with superior tissue visualization compared to X-ray fluoroscopy.\n\nIt is commercially available immediately in CE-marked markets and in some U.S. configurations, marking the expansion of cardiac MRI from diagnosis to treatment environments.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Philips expands cardiac MRI into treatment with new Imricor-powered iMR lab solution."},"keyFigures":null,"quotedText":"Our ambition is not only to advance what clinicians can see with MRI, but also what they can do with it","namedEntities":{"people":[{"name":"Ioannis Panagiotelis","role":"Business Leader, Magnetic Resonance at Philips"},{"name":"Steve Wedan","role":"Founder and CEO of Imricor"}],"products":["Interventional MR (iMR) lab solution","Philips 1.5T MR","NorthStar iMR mapping and guidance system","Advantage-MR EP Recorder/Stimulator","Vision-MR family of electrophysiology catheters","SmartHeart AI","BlueSeal helium-free MRI"],"companies":[{"name":"Royal Philips","ticker":"PHG"},{"name":"Imricor Medical Systems","ticker":"IMR","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Launch of the first commercially available Interventional MR lab solution expands Philips' cardiac portfolio into the treatment environment. While a strategic milestone expanding the company's addressable market, it is unlikely to cause significant immediate stock movement given the company's size."},"tickerRelevance":{"others":[{"ticker":"IMR","relevance":"partner"}],"primary":"PHG"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"product_launch","sectorWeight":"health_care"}},"event_type":"product_launch","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":3,"narrative":"Philips and Imricor launched the first commercially available Interventional MR lab solution, combining Philips' 1.5T MRI platform with Imricor's MR-compatible systems and consumables.\n\nThe solution enables MR-guided workflows for cardiac interventions like catheter ablation, offering radiation-free procedures with superior tissue visualization compared to X-ray fluoroscopy.\n\nIt is commercially available immediately in CE-marked markets and in some U.S. configurations, marking the expansion of cardiac MRI from diagnosis to treatment environments.","key_figures":null,"named_entities":{"people":[{"name":"Ioannis Panagiotelis","role":"Business Leader, Magnetic Resonance at Philips"},{"name":"Steve Wedan","role":"Founder and CEO of Imricor"}],"products":["Interventional MR (iMR) lab solution","Philips 1.5T MR","NorthStar iMR mapping and guidance system","Advantage-MR EP Recorder/Stimulator","Vision-MR family of electrophysiology catheters","SmartHeart AI","BlueSeal helium-free MRI"],"companies":[{"name":"Royal Philips","ticker":"PHG"},{"name":"Imricor Medical Systems","ticker":"IMR","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T19:28:22.632Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"large-cap","eventGravity":"product_launch","sectorWeight":"health_care"}},"durationMs":82421,"modelName":"glm-4.7"}}